Page last updated: 2024-12-09

6-methoxy-2-(3-methoxyphenyl)-1-benzopyran-4-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID676293
CHEMBL ID3039144
CHEBI ID107657
SCHEMBL ID516389

Synonyms (44)

Synonym
BRD-K47724892-001-02-2
DIVK1C_006256
KBIO1_001200
SDCCGMLS-0066760.P001
SPECTRUM4_001729
SPECTRUM_000645
BSPBIO_003287
SPECTRUM5_000498
KBIO2_001125
KBIOGR_002118
KBIOSS_001125
KBIO3_002507
KBIO2_003693 ,
KBIO2_006261
SPECTRUM3_001624
SPECTRUM2_000031
SPECPLUS_000160
SPBIO_000121
NCGC00178161-01
6,3'-dimethoxyflavone
CHEBI:107657
LMPK12110103
6-methoxy-2-(3-methoxyphenyl)chromen-4-one
CHEMBL3039144
CCG-38344
4h-1-benzopyran-4-one,6-methoxy-2-(3-methoxyphenyl)-
79786-40-6
SCHEMBL516389
AKOS024282378
4h-1-benzopyran-4-one, 6-methoxy-2-(3-methoxyphenyl)-
LLLIKVGWTVPYAL-UHFFFAOYSA-N
Q27185979
6-methoxy-2-(3-methoxyphenyl)-1-benzopyran-4-one
mfcd00143489
6,3'-dimethoxyflavone, aldrichcpr
DTXSID50350264
sr-05000002533
SR-05000002533-1
FT-0726184
6-methoxy-2-(3-methoxyphenyl)-4h-chromen-4-one
BRD-K47724892-001-03-0
(r)-3-amino-3-(3-fluoro-phenyl)-propionicacid
PD001270
6,3'-dimethoxy flavone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
flavonoidsAny organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them.
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1831525Inhibition of CK2 (unknown origin) at 1 uM relative to control2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
AID1831527Antiproliferative activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
AID1860354Inhibition of CYP450 in human liver microsomes assessed as inhibition of EpETrE formation at 10 uM in presence of arachidonic acid and NADPH by multi-enzyme assay based LC-MS/MS analysis relative to control
AID1831524Inhibition of BRD4 (unknown origin) at 1 uM incubated for 2 hrs by TR-FRET assay relative to control2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
AID1831526Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
AID1860353Inhibition of CYP450 in human liver microsomes assessed as inhibition of 20-HETE formation at 10 uM in presence of arachidonic acid and NADPH by multi-enzyme assay based LC-MS/MS analysis relative to control
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1860355Selectivity index, log ratio of Inhibition of CYP450 in human liver microsomes assessed as inhibition of EpETrE formation in presence of arachidonic acid to Inhibition of CYP450 in human liver microsomes assessed as inhibition of 20-HETE formation in pres
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.82 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]